<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35505609</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1542-0086</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Biophysical journal</Title><ISOAbbreviation>Biophys J</ISOAbbreviation></Journal><ArticleTitle>Toxic SOD1 trimers are off-pathway in the formation of amyloid-like fibrils in ALS.</ArticleTitle><Pagination><StartPage>2084</StartPage><EndPage>2095</EndPage><MedlinePgn>2084-2095</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bpj.2022.04.037</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-3495(22)00365-4</ELocationID><Abstract><AbstractText>Accumulation of insoluble amyloid fibrils is widely studied as a critical factor in the pathology of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. Misfolded Cu, Zn superoxide dismutase (SOD1) was the first protein linked to ALS, and non-native SOD1 trimeric oligomers were recently linked to cytotoxicity, while larger oligomers were protective to cells. The balance between trimers and larger aggregates in the process of SOD1 aggregation is, thus, a critical determinant of potential therapeutic approaches to treat ALS. However, it is unknown whether these trimeric oligomers are a necessary intermediate for larger aggregate formation or a distinct off-pathway species competing with fibril formation. Depending on the on- or off-pathway scenario of trimer formation, we expect drastically different therapeutic approaches. Here, we show that the toxic SOD1 trimer is an off-pathway intermediate competing with protective fibril formation. We design mutant SOD1 constructs that remain in a trimeric state (super-stable trimers) and show that stabilizing the trimeric SOD1 prevents formation of fibrils in&#xa0;vitro and in a motor neuron-like cell model (NSC-34). Using size exclusion chromatography, we track the aggregation kinetics of purified SOD1 and show direct competition of trimeric SOD1 with larger oligomer and fibril formation. Finally, we show the trimer is structurally independent of both larger soluble oligomers and insoluble fibrils using circular dichroism spectroscopy and limited proteolysis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Biophysical Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hnath</LastName><ForeName>Brianna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania; Department of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dokholyan</LastName><ForeName>Nikolay V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania; Department of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania; Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, Pennsylvania. Electronic address: dokh@psu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM134864</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071675</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD030490</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biophys J</MedlineTA><NlmUniqueID>0370626</NlmUniqueID><ISSNLinking>0006-3495</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="Y">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35505609</ArticleId><ArticleId IdType="pmc">PMC9247475</ArticleId><ArticleId IdType="doi">10.1016/j.bpj.2022.04.037</ArticleId><ArticleId IdType="pii">S0006-3495(22)00365-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosen D.R., Siddique T., et al. Brown R.H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364:359&#x2013;362. doi: 10.1038/364362c0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364362c0</ArticleId><ArticleId IdType="pubmed">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., et al. Akkari P.A. ALS genetics, mechanisms, and therapeutics: where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; B., Lehmann M., et al. Gros-Louis F. Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. Sci. Rep. 2018;8:14223. doi: 10.1038/s41598-018-31773-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31773-z</ArticleId><ArticleId IdType="pmc">PMC6155098</ArticleId><ArticleId IdType="pubmed">30242181</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K., Jonsson P.A., et al. Br&#xe4;nnstr&#xf6;m T. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One. 2010;5:e11552. doi: 10.1371/journal.pone.0011552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011552</ArticleId><ArticleId IdType="pmc">PMC2904380</ArticleId><ArticleId IdType="pubmed">20644736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox K.C., Zhou L., et al. Dokholyan N.V. Modifications of superoxide dismutase (SOD1) in human Erythrocytes. J.&#xa0;Biol. Chem. 2009;284:13940&#x2013;13947. doi: 10.1074/jbc.m809687200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.m809687200</ArticleId><ArticleId IdType="pmc">PMC2679493</ArticleId><ArticleId IdType="pubmed">19299510</ArticleId></ArticleIdList></Reference><Reference><Citation>Redler R.L., Wilcox K.C., et al. Dokholyan N.V. Glutathionylation at Cys-111 induces dissociation of wild type and FALS mutant SOD1 dimers. Biochemistry. 2011;50:7057&#x2013;7066. doi: 10.1021/bi200614y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi200614y</ArticleId><ArticleId IdType="pmc">PMC3281512</ArticleId><ArticleId IdType="pubmed">21739997</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor E.A., Ding F., Dokholyan N.V. Structural and thermodynamic effects of post-translational modifications in mutant and wild type Cu, Zn superoxide dismutase. J.&#xa0;Mol. Biol. 2011;408:555&#x2013;567. doi: 10.1016/j.jmb.2011.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.03.004</ArticleId><ArticleId IdType="pmc">PMC3082150</ArticleId><ArticleId IdType="pubmed">21396374</ArticleId></ArticleIdList></Reference><Reference><Citation>Redler R.L., Fee L., et al. Dokholyan N.V. Non-native soluble oligomers of Cu/Zn superoxide dismutase (SOD1) contain a conformational Epitope linked to cytotoxicity in amyotrophic lateral sclerosis (ALS) Biochemistry. 2014;53:2423&#x2013;2432. doi: 10.1021/bi500158w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi500158w</ArticleId><ArticleId IdType="pmc">PMC4004233</ArticleId><ArticleId IdType="pubmed">24660965</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja N.A., Veldink J.H., et al. van den Berg L.H. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph. Lateral Scler. 2009;10:302&#x2013;309. doi: 10.3109/17482960802455416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802455416</ArticleId><ArticleId IdType="pubmed">19922117</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W.-C., Liang J.-Z., et al. Liang Y. Pathological hydrogen peroxide triggers the fibrillization of wild-type SOD1 via sulfenic acid modification of Cys-111. Cell Death Dis. 2018;9:67. doi: 10.1038/s41419-017-0106-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0106-4</ArticleId><ArticleId IdType="pmc">PMC5833406</ArticleId><ArticleId IdType="pubmed">29358575</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor E.A., Mowrey D.D., Dokholyan N.V. &#x3b2;-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology. PLoS Comput. Biol. 2019;15:e1007225. doi: 10.1371/journal.pcbi.1007225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1007225</ArticleId><ArticleId IdType="pmc">PMC6668853</ArticleId><ArticleId IdType="pubmed">31323035</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare S.D., Caplow M., Dokholyan N.V. FALS mutations in Cu, Zn superoxide dismutase destabilize the dimer and increase dimer dissociation propensity: a large-scale thermodynamic analysis. Amyloid. 2006;13:226&#x2013;235. doi: 10.1080/13506120600960486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13506120600960486</ArticleId><ArticleId IdType="pubmed">17107883</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw B., Valentine J. How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? Trends Biochem. Sci. 2007;32:78&#x2013;85. doi: 10.1016/j.tibs.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2006.12.005</ArticleId><ArticleId IdType="pubmed">17208444</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare S.D., Wilcox K.C., et al. Dokholyan N.V. Sequence and structural determinants of Cu, Zn superoxide dismutase aggregation. Proteins Struct. Funct. Bioinforma. 2005;61:617&#x2013;632. doi: 10.1002/prot.20629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20629</ArticleId><ArticleId IdType="pubmed">16152647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding F., Dokholyan N.V. Dynamical roles of metal ions and the disulfide bond in Cu, Zn superoxide dismutase folding and aggregation. Proc. Natl. Acad. Sci. 2008;105:19696&#x2013;19701. doi: 10.1073/pnas.0803266105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0803266105</ArticleId><ArticleId IdType="pmc">PMC2604981</ArticleId><ArticleId IdType="pubmed">19052230</ArticleId></ArticleIdList></Reference><Reference><Citation>Timr S., Gnutt D., et al. Sterpone F. The unfolding journey of superoxide dismutase 1 barrels under crowding: atomistic simulations shed light on intermediate states and their interactions with Crowders. J.&#xa0;Phys. Chem. Lett. 2020;11:4206&#x2013;4212. doi: 10.1021/acs.jpclett.0c00699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.0c00699</ArticleId><ArticleId IdType="pubmed">32364389</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare S.D., Caplow M., Dokholyan N.V. The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 2004;101:15094&#x2013;15099. doi: 10.1073/pnas.0406650101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0406650101</ArticleId><ArticleId IdType="pmc">PMC524068</ArticleId><ArticleId IdType="pubmed">15475574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang L., Zetterstr&#xf6;m P., et al. Oliveberg M. SOD1 aggregation in ALS mice shows simplistic test tube behavior. Proc. Natl. Acad. Sci. 2015;112:9878&#x2013;9883. doi: 10.1073/pnas.1503328112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1503328112</ArticleId><ArticleId IdType="pmc">PMC4538623</ArticleId><ArticleId IdType="pubmed">26221023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers J.I., McMahon B., et al. Borchelt D.R. Relationship between mutant Cu/Zn superoxide dismutase 1 maturation and inclusion formation in cell models. J.&#xa0;Neurochem. 2017;140:140&#x2013;150. doi: 10.1111/jnc.13864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13864</ArticleId><ArticleId IdType="pmc">PMC5283795</ArticleId><ArticleId IdType="pubmed">27727458</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.A.I., Respondek M., et al. Akke M. Cu/Zn superoxide dismutase forms amyloid fibrils under near-physiological quiescent conditions: the roles of disulfide bonds and effects of denaturant. ACS Chem. Neurosci. 2017;8:2019&#x2013;2026. doi: 10.1021/acschemneuro.7b00162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00162</ArticleId><ArticleId IdType="pubmed">28585802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006;75:333&#x2013;366. doi: 10.1146/annurev.biochem.75.101304.123901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.75.101304.123901</ArticleId><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Redler R.L., Dokholyan N.V. Progress in Molecular Biology and Translational Science. Elsevier; 2012. The complex molecular biology of amyotrophic lateral sclerosis (ALS) pp. 215&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605887</ArticleId><ArticleId IdType="pubmed">22482452</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles T.P.J., Vendruscolo M., Dobson C.M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014;15:384&#x2013;396. doi: 10.1038/nrm3810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3810</ArticleId><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen P.H., Ramamoorthy A., et al. Derreumaux P. Amyloid oligomers: a joint Experimental/Computational perspective on Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, type II diabetes, and amyotrophic lateral sclerosis. Chem. Rev. 2021;121:2545&#x2013;2647. doi: 10.1021/acs.chemrev.0c01122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.0c01122</ArticleId><ArticleId IdType="pmc">PMC8836097</ArticleId><ArticleId IdType="pubmed">33543942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J.A., Higgins G.A. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185. doi: 10.1126/science.1566067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E., Mercken M., Strooper B.D. The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011;10:698&#x2013;712. doi: 10.1038/nrd3505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3505</ArticleId><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Winner B., Jappelli R., et al. Riek R. In&#xa0;vivo demonstration that -synuclein oligomers are toxic. Proc. Natl. Acad. Sci. 2011;108:4194&#x2013;4199. doi: 10.1073/pnas.1100976108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1100976108</ArticleId><ArticleId IdType="pmc">PMC3053976</ArticleId><ArticleId IdType="pubmed">21325059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L.N., Long H.W., et al. Chew L.Y. The toxicity of amyloid &#xdf; oligomers. Int. J. Mol. Sci. 2012;13:7303&#x2013;7327. doi: 10.3390/ijms13067303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms13067303</ArticleId><ArticleId IdType="pmc">PMC3397527</ArticleId><ArticleId IdType="pubmed">22837695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciarelli R., Fedele E. The amyloid cascade hypothesis in Alzheimer&#x2019;s disease: it&#x2019;s time to change our mind. Curr. Neuropharmacol. 2017;15:926&#x2013;935. doi: 10.2174/1570159x15666170116143743.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159x15666170116143743</ArticleId><ArticleId IdType="pmc">PMC5652035</ArticleId><ArticleId IdType="pubmed">28093977</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi E.S., Dokholyan N.V. SOD1 oligomers in amyotrophic lateral sclerosis. Curr. Opin. Struct. Biol. 2021;66:225&#x2013;230. doi: 10.1016/j.sbi.2020.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7965251</ArticleId><ArticleId IdType="pubmed">33465527</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor E.A., Fee L., et al. Dokholyan N.V. Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 2016;113:614&#x2013;619. doi: 10.1073/pnas.1516725113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1516725113</ArticleId><ArticleId IdType="pmc">PMC4725519</ArticleId><ArticleId IdType="pubmed">26719414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C., Beck M.V., et al. Dokholyan N.V. Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 2018;115:4661&#x2013;4665. doi: 10.1073/pnas.1800187115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800187115</ArticleId><ArticleId IdType="pmc">PMC5939103</ArticleId><ArticleId IdType="pubmed">29666246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakintt A., Chungt D.S., et al. Kirschnert D.A. On the nucleation and growth of amyloid ,8-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. U S&#xa0;A. 1996;5:1125&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40042</ArticleId><ArticleId IdType="pubmed">8577726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall D., Hirota N., Dobson C.M. A toy model for predicting the rate of amyloid formation from unfolded protein. J.&#xa0;Mol. Biol. 2005;351:195&#x2013;205. doi: 10.1016/j.jmb.2005.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.05.013</ArticleId><ArticleId IdType="pubmed">15993421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.-C., Nayak A., et al. McRae G.J. A three-stage kinetic model of amyloid fibrillation. Biophys.&#xa0;J. 2007;92:3448&#x2013;3458. doi: 10.1529/biophysj.106.098608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.106.098608</ArticleId><ArticleId IdType="pmc">PMC1853138</ArticleId><ArticleId IdType="pubmed">17325005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall D., Kardos J., et al. Goto Y. A multi-pathway perspective on protein aggregation: implications for control of the rate and extent of amyloid formation. FEBS Lett. 2015;589:672&#x2013;679. doi: 10.1016/j.febslet.2015.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2015.01.032</ArticleId><ArticleId IdType="pmc">PMC4349420</ArticleId><ArticleId IdType="pubmed">25647034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirota N., Edskes H., Hall D. Unified theoretical description of the kinetics of protein aggregation. Biophys. Rev. 2019;11:191&#x2013;208. doi: 10.1007/s12551-019-00506-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-019-00506-5</ArticleId><ArticleId IdType="pmc">PMC6441446</ArticleId><ArticleId IdType="pubmed">30888575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Ding F., Dokholyan N.V. Eris: an automated estimator of protein stability. Nat. Methods. 2007;4:466&#x2013;467. doi: 10.1038/nmeth0607-466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth0607-466</ArticleId><ArticleId IdType="pubmed">17538626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Ding F., Dokholyan N.V. Modeling backbone flexibility improves protein stability estimation. Structure. 2007;15:1567&#x2013;1576. doi: 10.1016/j.str.2007.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2007.09.024</ArticleId><ArticleId IdType="pubmed">18073107</ArticleId></ArticleIdList></Reference><Reference><Citation>Oztug Durer Z.A., et al. Valentine J.S. Loss of metal ions, disulfide reduction and mutations related to familial ALS promote formation of amyloid-like aggregates from superoxide dismutase. PLoS One. 2009;4:e5004. doi: 10.1371/journal.pone.0005004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005004</ArticleId><ArticleId IdType="pmc">PMC2659422</ArticleId><ArticleId IdType="pubmed">19325915</ArticleId></ArticleIdList></Reference><Reference><Citation>Girych M., Gorbenko G., et al. Kinnunen P. Combined thioflavin T&#x2013;Congo red fluorescence assay for amyloid fibril detection. Methods Appl. Fluoresc. 2016;4:034010. doi: 10.1088/2050-6120/4/3/034010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/2050-6120/4/3/034010</ArticleId><ArticleId IdType="pubmed">28355156</ArticleId></ArticleIdList></Reference><Reference><Citation>Medvedeva M., Barinova K., et al. Muronetz V. Naturally occurring cinnamic acid derivatives prevent amyloid transformation of alpha-synuclein. Biochimie. 2020;170:128&#x2013;139. doi: 10.1016/j.biochi.2020.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2020.01.004</ArticleId><ArticleId IdType="pubmed">31945397</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdolvahabi A., Shi Y., et al. Shaw B.F. Kaplan&#x2212;Meier meets Chemical kinetics: intrinsic rate of SOD1 amyloidogenesis decreased by subset of ALS mutations and cannot fully explain age of disease onset. ACS Chem. Neurosci. 2017;8:1378&#x2013;1389. doi: 10.1021/acschemneuro.7b00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00029</ArticleId><ArticleId IdType="pubmed">28290665</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L., Bertini I., et al. Carr&#xec; M.T. Interaction of Cisplatin with human superoxide dismutase. J.&#xa0;Am. Chem. Soc. 2012;134:7009&#x2013;7014. doi: 10.1021/ja211591n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja211591n</ArticleId><ArticleId IdType="pubmed">22471402</ArticleId></ArticleIdList></Reference><Reference><Citation>Parge H.E., Hallewellt R.A., Tainer J.A. Atomic structures of wild-type and thermostable mutant recombinant human Cu,Zn superoxide dismutase. Proc. Natl. Acad. Sci. USA. 1992;89:6109&#x2013;6113. doi: 10.1073/pnas.89.13.6109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.13.6109</ArticleId><ArticleId IdType="pmc">PMC49447</ArticleId><ArticleId IdType="pubmed">1463506</ArticleId></ArticleIdList></Reference><Reference><Citation>Higurashi T., Nosaka K., Kawata Y., et al. Unfolding and refolding of Escherichia coli chaperonin GroES is expressed by a three-state model. J.&#xa0;Mol. Biol. 1999;291:703&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia N.K., Srivastava A., et al. Deep S. Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity. Biochim. Biophys. Acta BBA - Proteins Proteomics. 2015;1854:426&#x2013;436. doi: 10.1016/j.bbapap.2015.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2015.01.014</ArticleId><ArticleId IdType="pubmed">25666897</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Pepe M., Fern&#xe1;ndez-Alvarez A.J., Boccaccio G.L. Life and work of stress granules and processing bodies: new insights into their formation and function. Biochemistry. 2018;57:2488&#x2013;2498. doi: 10.1021/acs.biochem.8b00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.8b00025</ArticleId><ArticleId IdType="pubmed">29595960</ArticleId></ArticleIdList></Reference><Reference><Citation>Musteikyte G., Ziaunys M., Smirnovas V. Methylene blue inhibits nucleation and elongation of SOD1 amyloid fibrils. PeerJ. 2020;8:e9719. doi: 10.7717/peerj.9719.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9719</ArticleId><ArticleId IdType="pmc">PMC7430317</ArticleId><ArticleId IdType="pubmed">32864220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia N.K., Modi P., et al. Deep S. Quercetin and baicalein act as potent antiamyloidogenic and fibril destabilizing agents for SOD1 fibrils. ACS Chem. Neurosci. 2020;11:1129&#x2013;1138. doi: 10.1021/acschemneuro.9b00677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00677</ArticleId><ArticleId IdType="pubmed">32208672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan S., Andersen J.K. Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson&#x2019;s disease? Mech. Ageing Dev. 2001;122:1499&#x2013;1510. doi: 10.1016/s0047-6374(01)00283-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0047-6374(01)00283-4</ArticleId><ArticleId IdType="pubmed">11511392</ArticleId></ArticleIdList></Reference><Reference><Citation>Birol M., Kumar S., et al. Miranker A.D. Conformational switching within dynamic oligomers underpins toxic gain-of-function by diabetes-associated amyloid. Nat. Commun. 2018;9:1312. doi: 10.1038/s41467-018-03651-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03651-9</ArticleId><ArticleId IdType="pmc">PMC5882805</ArticleId><ArticleId IdType="pubmed">29615609</ArticleId></ArticleIdList></Reference><Reference><Citation>Popugaeva E., Pchitskaya E., Bezprozvanny I. Dysregulation of intracellular Calcium signaling in Alzheimer&#x2019;s disease. Antioxid. Redox Signal. 2018;29:1176&#x2013;1188. doi: 10.1089/ars.2018.7506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2018.7506</ArticleId><ArticleId IdType="pmc">PMC6157344</ArticleId><ArticleId IdType="pubmed">29890840</ArticleId></ArticleIdList></Reference><Reference><Citation>Atlasi R.S., Malik R., et al. Bitan G. Investigation of anti-SOD1 antibodies yields new structural insight into SOD1 misfolding and surprising behavior of the antibodies themselves. ACS Chem. Biol. 2018;13:2794&#x2013;2807. doi: 10.1021/acschembio.8b00729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.8b00729</ArticleId><ArticleId IdType="pmc">PMC6475120</ArticleId><ArticleId IdType="pubmed">30110532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerman A., Liu H.-N., et al. Chakrabartty A. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. (Berl.) 2010;119:335&#x2013;344. doi: 10.1007/s00401-010-0646-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0646-5</ArticleId><ArticleId IdType="pubmed">20111867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y., Homma K., Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv. Biol. Regul. 2016;60:95&#x2013;104. doi: 10.1016/j.jbior.2015.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2015.10.006</ArticleId><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Bui A., et al. Ravits J. Misfolded SOD1 is not a primary component of sporadic ALS. Acta Neuropathol. (Berl.) 2017;134:97&#x2013;111. doi: 10.1007/s00401-017-1688-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1688-8</ArticleId><ArticleId IdType="pmc">PMC5472502</ArticleId><ArticleId IdType="pubmed">28247063</ArticleId></ArticleIdList></Reference><Reference><Citation>Auclair J.R., Boggio K.J., et al. Agar J.N. Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 2010;107:21394&#x2013;21399. doi: 10.1073/pnas.1015463107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1015463107</ArticleId><ArticleId IdType="pmc">PMC3003092</ArticleId><ArticleId IdType="pubmed">21098299</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairoalsindi O.A., Abuzinadah A.R. Maximizing the survival of amyotrophic lateral sclerosis patients: Current perspectives. Neurol. Res. Int. 2018;2018:1&#x2013;12. doi: 10.1155/2018/6534150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6534150</ArticleId><ArticleId IdType="pmc">PMC6109498</ArticleId><ArticleId IdType="pubmed">30159171</ArticleId></ArticleIdList></Reference><Reference><Citation>Capper M.J., Wright G.S.A., et al. Hasnain S.S. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat. Commun. 2018;9:1693. doi: 10.1038/s41467-018-04114-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04114-x</ArticleId><ArticleId IdType="pmc">PMC5923229</ArticleId><ArticleId IdType="pubmed">29703933</ArticleId></ArticleIdList></Reference><Reference><Citation>Amporndanai K., Rogers M., et al. Hasnain S.S. Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis. EBioMedicine. 2020;59:102980. doi: 10.1016/j.ebiom.2020.102980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102980</ArticleId><ArticleId IdType="pmc">PMC7456458</ArticleId><ArticleId IdType="pubmed">32862101</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., et al. Ferguson T.A. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N.&#xa0;Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/nejmoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieschke J., Herbst M., et al. Wanker E.E. Small-molecule conversion of toxic oligomers to nontoxic &#x3b2;-sheet&#x2013;rich amyloid fibrils. Nat. Chem. Biol. 2012;8:93&#x2013;101. doi: 10.1038/nchembio.719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.719</ArticleId><ArticleId IdType="pubmed">22101602</ArticleId></ArticleIdList></Reference><Reference><Citation>Goscin S.A., Fridovich I. The purification and properties of superoxide dismutase from Saccharomyces cerevisiae. Biochim. Biophys. Acta BBA - Enzymol. 1972;289:276&#x2013;283. doi: 10.1016/0005-2744(72)90078-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-2744(72)90078-2</ArticleId><ArticleId IdType="pubmed">4346514</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdolvahabi A., Shi Y., et al. Shaw B.F. How do gyrating beads accelerate amyloid fibrillization? Biophys.&#xa0;J. 2017;112:250&#x2013;264. doi: 10.1016/j.bpj.2016.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2016.12.004</ArticleId><ArticleId IdType="pmc">PMC5266089</ArticleId><ArticleId IdType="pubmed">28122213</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M., Yang Y., et al. Siddique T. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72:1634&#x2013;1639. doi: 10.1212/01.wnl.0000343509.76828.2a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343509.76828.2a</ArticleId><ArticleId IdType="pmc">PMC2683645</ArticleId><ArticleId IdType="pubmed">19176896</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>